NEW YORK, June 12, 2025
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc.
("Semler" or the "Company") (NASDAQ: SMLR). Such investors are advised to contact
Danielle Peyton at
danielle.peyton@pomlaw.com
or 646-581-9980, ext. 7980.
The investigation concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Click here for information about joining the class action
On February 28, 2025, Semler filed its annual report for 2024, in which it disclosed that "there is a risk that [U.S. Department of Justice ('DOJ')] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages."
Semler also disclosed receipt of an initial civil investigative demand from the DOJ in July 2017 regarding Semler's claims for reimbursement related to its peripheral artery disease QuantaFlo device.
Semler further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful.
On this news, Semler's stock price fell $4.03 per share, or 9.4%, to close at $38.89 per share on March 3, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.
The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Danielle Peyton Pomerantz LLP
danielle.peyton@pomlaw.com
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
